TAKANO Co.,Ltd. Q2 FY2026 earnings call

• Company-Wide Financial Overview

  • H1 FY2025 achieved revenue growth and a return to net profitability: consolidated revenue is 10.7 billion yen, up from 9.6 billion yen in the prior-year period; operating profit is 92 million yen, ordinary profit is 173 million yen, reversing the prior-year H1 deficit.
  • Capital expenditure in H1 was higher than usual, concentrated in solar energy investments and core accounting system renewal. R&D spending was 266 million yen, a slight nominal decrease from prior periods with no reduction in R&D commitment.

• New Growth Initiatives

  • Space Business Entry (Industrial Equipment Division): Won a contract from Mitsubishi Heavy Industries to develop valves for the I-Hab international habitat module of JAXA's Gateway lunar orbital outpost. The company is positioning this as an early foothold in the fast-growing private space industry and will continue pursuing multiple opportunities in the sector.
  • Allergy Clinical Testing Business (Medical Division): As a new entrant to the medical device industry, the company has built industry connections with leading allergy specialists, hosted educational seminars, signed contracts with major domestic distributors, and achieved consistent sales growth, with a business model built on recurring consumable test reagent revenue.
  • Structural Reform for Inspection & Measurement Equipment Segment: Continued shifting capacity from the mature FPD business to semiconductor and film inspection. The segment has completed organizational restructuring into business-unit teams, increased hiring for development, and is evaluating a relocation of its cramped Saitama semiconductor facility to expand capacity. R&D investment is set at 1.5x the level of the prior mid-term plan. New products include upgraded WM-series particle inspection tools and the new ALTAX-300EX for 2D/3D microbump inspection, launched at SEMICON Japan 2025.

1. Housing & Lifestyle-Related Equipment: Slight year-over-year (YoY) revenue increase in H1 FY2025. Office furniture sub-segment is growing due to persistently low office vacancy rates and active corporate office investment. The new allergy clinical testing business (Medical Division) achieved revenue growth and is performing well. Revenue contribution not specified.
2. Inspection & Measurement Equipment: H1 FY2025 revenue is 2.986 billion yen, a 53.7% YoY increase, and the segment turned profitable after a prior-year loss. Within the segment, revenue breakdown is: 1.354 billion yen (50% of segment revenue) for semiconductor, 766 million yen (28%) for film, 589 million yen (21%) for FPD (flat panel display).
3. Industrial Equipment & Others: H1 FY2025 revenue is down 2.4% YoY, with a steep decline over a 3-period horizon, and the segment recorded an operating loss in H1. Weakness is driven by difficult market conditions for legacy/mature semiconductors (power semiconductors and discrete semiconductors), which the segment serves. Revenue contribution not specified.
4. Exterior: Not disclosed.
5. Machinery & Tools: Not disclosed.

• Full-year FY2025 consolidated guidance projects year-over-year revenue and profit growth: full-year revenue is projected at 25 billion yen, a slight increase from the prior full year's ~24 billion yen; operating profit is projected at 750 million yen, up from 451 million yen prior; ordinary profit is projected at 850 million yen, up from 528 million yen prior.
• H2 FY2025 consolidated revenue is projected to be roughly flat YoY at 14.2 billion yen, resulting in full-year growth driven by the strong H1 performance.
• For the Inspection & Measurement Equipment segment, full-year revenue guidance is 6.183 billion yen, with a breakdown of 2.679 billion yen for semiconductor, 1.825 billion yen for film, and 1.431 billion yen for FPD. Management expects continued balanced sales between H1 and H2, with slightly higher sales in H2.
• Management maintains a positive medium-term outlook for the semiconductor sector: while near-term conditions are weak for power and legacy semiconductors, management expects a mid-term recovery, and remains bullish on growth in AI-driven semiconductor demand. Long-term growth is also expected for film inspection demand from automotive battery and electronic component materials sectors.

• The Industrial Equipment segment and semiconductor-related portions of the Inspection & Measurement segment are heavily exposed to cyclical downturns in the global semiconductor industry, particularly in the weak legacy/power semiconductor sub-sector, which has driven near-term revenue and order declines.
• Large new capital investment plans for the FPD sector, including in the Indian market, remain highly uncertain and management is not counting on near-term growth from this demand.
• European and North American demand for inspection equipment has weakened, due in part to sluggish investment from power and compound semiconductor customers and customer hesitation caused by US trade tariffs.
• Legacy FPD demand remains weak, with large new customer investments on hold, limiting growth potential for that sub-segment.
• The new space business and allergy clinical testing businesses are still in early stages, with no guarantee they will scale to material revenue contribution for the company.

Q: Is the JAXA Gateway valve contract just a one-off project, and do you have a plan to grow space business into a meaningful revenue source? / A: Management confirms no large-scale revenue contribution from space business is mapped out at this stage. The industry is in an early, fluid growth period as it shifts from government to private leadership, and Takano is receiving multiple new inquiries. The company's strategy is to trial multiple approaches to space business rather than targeting immediate scale, and aims to generate incremental long-term returns from early market entry. (3-4 sentences)

Q: What is your level of inquiry and activity in perovskite PV inspection, and do you have existing orders for this segment? / A: Takano currently has concrete, specific inquiries for perovskite PV inspection, and is actively working toward securing an order. While most current discussions are for glass-related perovskite applications rather than film production process applications, the company views perovskite as a high-growth future market and will continue pursuing opportunities actively. (3-4 sentences)

Q: What is the expected long-term scale of the allergy clinical testing business? / A: Management expects the business to reach a scale of hundreds of millions of yen, not billions of yen, in the near to medium term. The business has an attractive recurring revenue model: diagnostic devices are placed at medical institutions, with ongoing repeat sales of consumable test reagents that deliver stable profit. While accurate near-term sales forecasting is difficult, management sees solid potential for consistent profitable growth from the business. (4 sentences)

Q: What is your outlook for orders and sales for semiconductor-related products in the Industrial Equipment segment? / A: Management cannot share specific detailed numbers, as the semiconductor sector is highly cyclical and clear forecasting is difficult. The segment's semiconductor business will generally track overall industry trends for legacy and power semiconductors, so market consensus forecasts can be taken as a baseline. The Industrial Equipment segment serves many diversified markets outside of semiconductors including medical devices, textile machinery, space, and ATMs, so the core priority is driving balanced overall segment growth across these multiple end markets. (4 sentences)